Leveraging multi-cancer blood tests to improve diagnostic efficiency for patients with nonspecific signs and symptoms.
作者信息
Singal Amit G, Kurtzman Kathryn N, Thompson Matthew J
机构信息
Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX 75390, USA.
GRAIL, Inc., Menlo Park, CA 94025, USA.
出版信息
Future Oncol. 2024;20(34):2603-2607. doi: 10.1080/14796694.2024.2388505. Epub 2024 Aug 28.
Abstract
摘要
相似文献
1
Leveraging multi-cancer blood tests to improve diagnostic efficiency for patients with nonspecific signs and symptoms.利用多癌血液检测提高非特异性体征和症状患者的诊断效率。
Future Oncol. 2024;20(34):2603-2607. doi: 10.1080/14796694.2024.2388505. Epub 2024 Aug 28.
2
Symptoms, signs, and tests: The general practitioner's comprehensive approach towards a cancer diagnosis.症状、体征与检查：全科医生对癌症诊断的综合方法
Scand J Prim Health Care. 2015;33(3):170-7. doi: 10.3109/02813432.2015.1067512. Epub 2015 Sep 16.
3
Diagnostic center for primary care patients with nonspecific symptoms and suspected cancer: compliance to workflow and accuracy of tests and examinations.初级保健患者非特异性症状和疑似癌症的诊断中心：工作流程的遵守情况以及检查和检验的准确性。
Scand J Prim Health Care. 2021 Jun;39(2):148-156. doi: 10.1080/02813432.2021.1913892. Epub 2021 May 6.
4
Current Challenges of Methylation-Based Liquid Biopsies in Cancer Diagnostics.基于甲基化的液体活检在癌症诊断中的当前挑战
Cancers (Basel). 2024 May 24;16(11):2001. doi: 10.3390/cancers16112001.
5
Predictive value of abnormal blood tests for detecting cancer in primary care patients with nonspecific abdominal symptoms: A population-based cohort study of 477,870 patients in England.异常血液检查对初级保健中具有非特异性腹部症状的患者癌症检测的预测价值：一项基于人群的队列研究，纳入了英格兰 477870 例患者。
PLoS Med. 2024 Jul 30;21(7):e1004426. doi: 10.1371/journal.pmed.1004426. eCollection 2024 Jul.
6
Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms.血液样本代谢组学生物标志物可识别具有非特异性症状的混合患者人群中的癌症。
Clin Cancer Res. 2022 Apr 14;28(8):1651-1661. doi: 10.1158/1078-0432.CCR-21-2855.
7
Modern parameterization and explanation techniques in diagnostic decision support system: a case study in diagnostics of coronary artery disease.现代参数化和解释技术在诊断决策支持系统中的应用：以冠心病诊断为例。
Artif Intell Med. 2011 Jun;52(2):77-90. doi: 10.1016/j.artmed.2011.04.009. Epub 2011 Jun 8.
8
Urinalysis in acute care of adults: pitfalls in testing and interpreting results.成人急症护理中的尿液分析：检测和解释结果中的陷阱。
Open Forum Infect Dis. 2014 Jun 23;1(1):ofu019. doi: 10.1093/ofid/ofu019. eCollection 2014 Mar.
9
Nonspecific Signs and/or Symptoms of Cancer: A Retrospective, Observational Analysis from a Secondary Care, US Community Oncology Dataset.癌症的非特异性体征和/或症状：来自美国社区肿瘤学二级护理观察性分析数据集的回顾性分析。
Curr Oncol. 2024 Jun 25;31(7):3643-3656. doi: 10.3390/curroncol31070268.
10
Technology and Future of Multi-Cancer Early Detection.多癌早期检测的技术与未来
Life (Basel). 2024 Jun 29;14(7):833. doi: 10.3390/life14070833.
引用本文的文献
1
Cell-Free DNA: Features and Attributes Shaping the Next Frontier in Liquid Biopsy.游离DNA：塑造液体活检下一个前沿领域的特征与属性
Mol Diagn Ther. 2025 May;29(3):277-290. doi: 10.1007/s40291-025-00773-x. Epub 2025 Apr 16.
本文引用的文献
1
Shifting the Cancer Screening Paradigm: Developing a Multi-Biomarker Class Approach to Multi-Cancer Early Detection Testing.转变癌症筛查模式：开发用于多癌早期检测测试的多生物标志物分类方法。
Life (Basel). 2024 Jul 24;14(8):925. doi: 10.3390/life14080925.
2
Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study.基于血液的多种癌症早期检测（PATHFINDER）：一项前瞻性队列研究。
Lancet. 2023 Oct 7;402(10409):1251-1260. doi: 10.1016/S0140-6736(23)01700-2.
3
Cell-free DNA approaches for cancer early detection and interception.无细胞游离 DNA 方法在癌症早期检测和干预中的应用。
J Immunother Cancer. 2023 Sep;11(9). doi: 10.1136/jitc-2022-006013.
4
Performance of a Cell-Free DNA-Based Multi-cancer Detection Test in Individuals Presenting With Symptoms Suspicious for Cancers.基于游离细胞 DNA 的多癌种检测试验在出现疑似癌症症状的个体中的表现。
JCO Precis Oncol. 2023 Jul;7:e2200679. doi: 10.1200/PO.22.00679.
5
Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort study.英国和威尔士因癌症检查而转诊的有症状患者的多癌早期检测试验（SYMPLIFY）：一项大规模观察性队列研究
Lancet Oncol. 2023 Jul;24(7):733-743. doi: 10.1016/S1470-2045(23)00277-2. Epub 2023 Jun 20.
6
Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set.使用独立验证集对靶向甲基化的多癌种早期检测测试进行临床验证。
Ann Oncol. 2021 Sep;32(9):1167-1177. doi: 10.1016/j.annonc.2021.05.806. Epub 2021 Jun 24.
7
Reviewing the impact of 11 national Be Clear on Cancer public awareness campaigns, England, 2012 to 2016: A synthesis of published evaluation results.审查 11 项全国“爱康工程”公众宣传活动对英格兰的影响，2012 年至 2016 年：已发表评估结果的综合报告。
Int J Cancer. 2021 Mar 1;148(5):1172-1182. doi: 10.1002/ijc.33277. Epub 2020 Nov 7.
8
Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention.血液检测结合 PET-CT 筛查癌症并指导干预的可行性。
Science. 2020 Jul 3;369(6499). doi: 10.1126/science.abb9601. Epub 2020 Apr 28.
9
The frequency, nature and impact of GP-assessed avoidable delays in a population-based cohort of cancer patients.基于人群的癌症患者队列中全科医生评估的可避免延迟的频率、性质和影响。
Cancer Epidemiol. 2020 Feb;64:101617. doi: 10.1016/j.canep.2019.101617. Epub 2019 Dec 3.
10
Missed diagnosis of cancer in primary care: Insights from malpractice claims data.基层医疗中癌症的漏诊：医疗事故索赔数据的启示
J Healthc Risk Manag. 2019 Oct;39(2):19-29. doi: 10.1002/jhrm.21385. Epub 2019 Jul 23.
Zotero 插件